News stories about Immunomedics (NASDAQ:IMMU) have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Immunomedics earned a news impact score of 0.12 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.9114753234454 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:

IMMU has been the subject of several recent analyst reports. BidaskClub raised shares of Immunomedics from a “hold” rating to a “buy” rating in a research report on Friday, April 20th. ValuEngine downgraded shares of Immunomedics from a “strong-buy” rating to a “buy” rating in a research report on Monday, June 11th. B. Riley initiated coverage on shares of Immunomedics in a research report on Thursday, June 7th. They set a “buy” rating and a $53.00 price objective for the company. Zacks Investment Research raised shares of Immunomedics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 16th. Finally, Wells Fargo & Co raised their price objective on shares of Immunomedics from $25.00 to $31.00 and gave the stock an “outperform” rating in a research report on Monday, June 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $31.50.

Shares of IMMU stock opened at $21.00 on Friday. The company has a market cap of $3.95 billion, a PE ratio of -25.93 and a beta of 1.72. Immunomedics has a 52 week low of $7.68 and a 52 week high of $27.33. The company has a debt-to-equity ratio of 2.81, a current ratio of 3.94 and a quick ratio of 3.94.

In related news, Director Venbio Select Advisor Llc acquired 575,000 shares of Immunomedics stock in a transaction dated Friday, June 15th. The stock was bought at an average price of $24.00 per share, with a total value of $13,800,000.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 14.80% of the company’s stock.

About Immunomedics

Immunomedics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers.

Read More: Price to Earnings Ratio (PE)

Insider Buying and Selling by Quarter for Immunomedics (NASDAQ:IMMU)

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with's FREE daily email newsletter.